VERSATIS - Efficacy and Safety of Lidocaine 5% Plasters (Versatis® 5%) in Child, Adolescents and Young Adults With Neuropathic Pains or Vasoocclusive Sickle Cell Crisis Pains

Fecha de inicio: 1 de marzo de 2011

Inclusion Criteria: * 6 years \<= Age \<= 21 years * With: * Pure or mixed, localized, superficial neuropathic pains for which the neuropathic pain score DN4 is greater than or equal to 4 * Or localized, superficial sickle cell crisis pains Insufficiently relieved by commonly used therapeutic (analgesic level II or III and / or antiepileptic drugs, and / or neuroleptics) - GCS \> 12 * Covered by a medical insurance * Signed written informed consent form(for minors unemancipated, permission will be given by holders of parental authority) Exclusion Criteria: * Clinical condition not permitting data reporting (impaired consciousness) * Painful area with an surface greater than: * 150 cm² for a patient with total body surface area \< 1 m² * 300 cm² for a patient with 1 m² \< total body surface area \< 1.5 m² * 450 cm² for a patient with total body surface area \> 1.5 m² * Existence of a statement for the use of lidocaine 5% (VERSATIS® 5%) plaster as defined in the summary of product characteristics, as: * known hypersensitivity to the active substance or excipients * known hypersensitivity to other local anesthetics such as amide (eg bupivacaine, etidocaine, mepivacaine and prilocaine) * inflammatory or injured skin (active lesions of herpes zoster, dermatitis or wounds) * Severe cardiac insufficiency * Severe renal insufficiency * Severe hepatic insufficiency * Patient receiving anti-arrhythmic class I or other local anesthetics. * Pregnant or lactating female or female of child-bearing potential not employing adequate contraception * Patient included in another clinical trial on the management of pain